{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:24:30Z","timestamp":1720675470967},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.lpm.2012.06.019","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T04:49:11Z","timestamp":1348721351000},"page":"977-982","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Traitement de l\u2019h\u00e9patite chronique virale C par trith\u00e9rapie"],"prefix":"10.1016","volume":"42","author":[{"given":"Denis","family":"Ouzan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2012.06.019_bib0005","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2012.06.019_bib0010","unstructured":"Prise de position de l\u2019AFEF sur les trith\u00e9rapies dans la prise en charge des malades atteints d\u2019h\u00e9patite C. Avril 20015 (Actualisation au 30\/11\/2011). http:\/\/www.afef.asso.fr\/bibliotheque\/recommandations"},{"key":"10.1016\/j.lpm.2012.06.019_bib0015","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2012.06.019_bib0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a Randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1\u00a0hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.lpm.2012.06.019_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0399-8320(07)89433-4","article-title":"Comment obtenir une efficacit\u00e9 optimale du traitement actuel de l\u2019h\u00e9patite chronique virale C","volume":"31","author":"Ouzan","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of HCV infection","volume":"55","author":"Craxi","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0050","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for pr\u00e9viously untreated chronic HCV infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Eng J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1\u00a0infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0060","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response \u2013 Guided telaprevir combinationtreatment for HCV Infection","volume":"364","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0065","doi-asserted-by":"crossref","first-page":"S543","DOI":"10.1016\/S0168-8278(11)61371-8","article-title":"Telaprevir substantially improved SVR rates accross all IL28B genotypes in the Advance trial","volume":"54","author":"Jacobson","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0070","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60014-7","article-title":"IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1\u00a0treated with boceprevir combination therapy","volume":"54","author":"Poordad","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0075","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retraitement of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0080","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1\u00a0infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2012.06.019_bib0085","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","article-title":"Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir\/peg-IFN\/ribavirin: retrospective analysis of the REALIZE study","volume":"54","author":"Pol","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0090","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S0168-8278(11)60478-9","article-title":"Anemia during treatment with peginterferon alfa-2B\/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients","volume":"54","author":"Bronowicki","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.lpm.2012.06.019_bib0095","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(11)60430-3","article-title":"Adherance to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1\u00a0treatment na\u00efve and peg-ribavirin treatment-failures treated with boceprevir plus peg-IFN alfa 2b\/ribavirin","volume":"54","author":"Gordon","year":"2011","journal-title":"J Hepatol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212004824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212004824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T08:51:58Z","timestamp":1542703918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498212004824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0755498212004824"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2012.06.019","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}